BUSINESS
03/18/2010 05:12 am ET Updated May 25, 2011

FDA May Tighten Rules On Omniscan, A GE MRI Drug

The U.S. Food and Drug Administration is weighing further regulation of three drugs used to create high-contrast images on MRI scans, based on a new analysis that suggests they carry a higher risk of causing a rare but potentially fatal disease.

The issue -- highlighted in an October story by BusinessWeek and ProPublica -- marks a setback for GE Healthcare (GE), which contends its product is no riskier than competing imaging drugs. FDA reviewers said GE's drug, Omniscan, had a disproportionally high number of reports of the disease compared with its peers.

Read more on BusinessWeek / ProPublica